Skip to main content
Porton Pharma Solutions Ltd. logo

Porton Pharma Solutions Ltd. — Investor Relations & Filings

Ticker · 300363 ISIN · CNE100001S57 LEI · 300300IQTJFHA0YRXE68 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,163 across all filing types
Latest filing 2024-04-09 Transaction in Own Shar…
Country CN China
Listing Shenzhen Stock Exchange 300363

About Porton Pharma Solutions Ltd.

https://www.porton.cn

Porton Pharma Solutions Ltd. is a global contract development and manufacturing organization (CDMO) providing end-to-end solutions for the pharmaceutical and biotechnology sectors. The company specializes in the development and manufacturing of small molecule APIs, intermediates, and drug products, while expanding its capabilities into biologics and cell and gene therapies. Its service portfolio encompasses process research and development, analytical services, pilot-scale production, and large-scale commercial manufacturing. Porton operates a network of R&D centers and manufacturing facilities designed to meet international regulatory standards, including those of the FDA and EMA. By leveraging an integrated technology platform, the company supports clients throughout the entire drug lifecycle, from preclinical development to commercialization, focusing on operational excellence and supply chain security.

Recent filings

Filing Released Lang Actions
关于回购公司股份实施完毕的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the completion of a share repurchase program by the company. It details the number of shares repurchased, the price range, compliance with regulatory requirements, and the intended use of the repurchased shares for employee incentive plans. The document does not contain financial statements or detailed financial analysis but is a formal disclosure of the share buyback completion. This fits the definition of a Transaction in Own Shares (POS) filing, which reports on the company's buyback of its own shares.
2024-04-09 Chinese
关于回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is a progress announcement regarding the company's share repurchase plan. It details the number of shares repurchased, the price range, total amount spent, and compliance with regulatory guidelines. It does not contain full financial statements or comprehensive financial analysis but rather updates on the share buyback activity. The document length is short (1037 characters) and focuses on the progress of a share repurchase program, which fits the definition of a Transaction in Own Shares (POS) filing rather than a full financial report or other categories.
2024-04-03 Chinese
关于控股子公司完成工商变更登记的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the completion of a business registration change for a wholly-owned subsidiary, including details about the share transfer and the new business license information. It does not contain financial statements, earnings data, or detailed management discussion. It is a regulatory announcement about corporate structure changes and administrative updates, not a full report or financial filing. The document length is short (1298 characters), and it is an announcement of a corporate event rather than a report itself. Therefore, it fits best under Regulatory Filings (RNS).
2024-04-03 Chinese
关于回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is a progress announcement regarding the company's share repurchase plan. It details the number of shares repurchased, prices, and compliance with regulatory guidelines. It does not contain full financial statements or detailed financial analysis, but rather updates on the share buyback activity. This fits the definition of a Transaction in Own Shares (POS) filing, which reports on the company's buyback or sale of its own shares.
2024-03-04 Chinese
关于2023年员工持股计划完成股票购买的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the completion of stock purchases under the company's 2023 employee stock ownership plan. It details the number of shares purchased, the funding sources, the lock-up period, and governance related to the plan. It does not contain financial statements or detailed financial performance data. The document is a formal disclosure about a capital-related event (employee stock ownership plan implementation and stock purchase completion). This fits best under the category of Capital/Financing Update (CAP), as it relates to changes in the company's capital structure through employee stock purchases.
2024-02-27 Chinese
关于参与认购投资基金份额的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Chongqing Boteng Pharmaceutical Technology Co., Ltd. regarding its participation in subscribing to investment fund shares. It details the transaction overview, parties involved, fund information, investment purpose, risks, and related disclosures. There is no financial statement or report data presented, nor is it a transcript, management report, or regulatory filing of financial results. The document is a formal announcement about a capital investment activity, specifically the company's investment in a private equity fund. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document length is over 6,500 characters and contains detailed information about the investment, supporting the CAP classification with high confidence.
2024-02-23 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.